PDSB News and Press, PDS Biotechnology Corporation From 05/27/26

2026-05-27 17:33:13 ET Image source: The Motley Fool. Wednesday, May 13, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-13 14:51:55 ET Image source: The Motley Fool. Wednesday, May 13, 2026 at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-05-13 10:11:47 ET More on PDS Biotechnology PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 proto...

2026-05-13 10:10:43 ET PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call May 13, 2026 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript

2026-05-13 07:10:27 ET More on PDS Biotechnology PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment Seeking Alpha’s Quant Rating on PDS Biotechnology...

Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and ki...

2026-05-12 12:05:57 ET More on PDS Biotechnology PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript PDS Biotech outlines accelerated regulatory timeline after VERSATILE-003 protocol amendment Seeking Alpha’s Quant Rating on PDS Biotechnology...

PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company...

78% Objective Response Rate (ORR) with PDS01ADC; Parallel trial without PDS01ADC had 35% ORR 2-year survival rate of >80%; Parallel trial without PDS01ADC resulted in 2-year survival rate of ~35% Trials performed in unresectable microsatellite stable (MSS) or mismatch repair-proficient (...

2026-03-30 12:02:42 ET More on PDS Biotechnology PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript Seeking Alpha’s Quant Rating on PDS Biotechnology Historical earnings data for PDS Biotechnology Financial information for PDS Biotec...